Randomized, Single-Blind, Active Comparator-controlled Study to Evaluate the Safety and Immunological Efficacy of GC3114 in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs GC 3114 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GC Pharma
- 08 May 2018 Status changed from recruiting to completed.
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 07 Dec 2017 New trial record